In November 2019, the FDA issued a Class I recall, the agency’s most serious type of recall, for the following models of the 600 Series Medtronic MiniMed Insulin Pumps:  

• Model 630 G (MMT-1715): Distributed/Sold from September 2016-October 2019
• Model 670 G (MMT 1780): Distributed/Sold from June 2017-August 2019

If you use a Medtronic insulin pump, you may check to see if your device has been recalled by finding your model number and reading Medtronic’s full safety notification.

Contact Us 

If you or a loved one suffered severe complications or tragically lost their life due to a defective Medtronic MiniMed insulin pump, you may have a claim. Complete this webform or call 1.800.768.4026 to contact attorney Esther Berezofsky for more information or to discuss a potential claim.  

Medtronic insulin pump side effects  

Medtronic’s allegedly defective insulin pumps put diabetic patients at risk of receiving too much or too little insulin, which could have potentially fatal results. 

Insulin overdose can cause hypoglycemia, a condition where a person’s blood sugar (glucose) is too low. Symptoms are severe and can include:  

• Brain injury
• Coma
• Seizures

Taking too little insulin can cause hyperglycemia, a condition where a person’s blood sugar is too high. Symptoms can include:  

• Loss of consciousness
• Seizure
• Death

Medtronic recall background

Medtronic has received more than 26,000 complaints regarding its 600 Series MiniMed insulin pumps, including reports of at least 2,175 injuries and at least one death. The device’s retainer ring, which holds the insulin cartridge in place, may malfunction, come loose or be damaged, allowing the insulin cartridge to shift inside of the pump. As a result, the device may over or under deliver insulin to the patient.  

Many Type I diabetics rely on insulin pumps to deliver insulin on a continual basis throughout the day, eliminating the need for daily injections. The proper functioning of both the insulin pump and infusion set is crucial. If not administered properly, the delivery of excess or insufficient insulin can cause serious harm. 

Our diabetes litigation experience   

In addition to our attorneys’ experience handling other insulin pump cases, we also have  investigated and litigated allegations that diabetes medicines caused complications, including working with hundreds of diabetic patients to review and file their medical drug lawsuits over Actos® and Duetact®, which have been linked to an increased risk of developing bladder cancer, as well as incretin mimetics Januvia®, Victoza®, Janumet® and Byetta® which are linked to pancreatic cancer. We previously reviewed claims involving SGLT2 Inhibitors Invokana®, Invokamet®, Farixga®, Xigduo XR®, Jardiance®, Glyxambi® and Synjardy®, which allegedly increased the risk of kidney failure.  

Our attorneys have the resources needed to thoroughly investigate and identify potentially harmful products, medical causation, compliance with FDA regulations, inadequate warnings, wrongdoing and other issues in medical products lawsuits.   

---

Consult a medical professional before stopping or changing any medication. 

Motley Rice LLC, a South Carolina Limited Liability Company, is engaged in the New Jersey practice of law through Motley Rice New Jersey LLC. Esther Berezofsky attorney responsible for New Jersey practice.